{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:39:49Z","timestamp":1792571989401,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05740-6","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:07:23Z","timestamp":1789549643000},"page":"5515-5532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ligustrazine with telmisartan mitigates the progression of diabetic cardiomyopathy by reducing ER stress, apoptosis, and myocardial fibrosis"],"prefix":"10.1007","volume":"481","author":[{"given":"Mansi Vinodkumar","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant R.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"8","key":"5740_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27(8):1879\u20131884","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"5740_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2613","volume":"45","author":"R Gonzalez-Manzanares","year":"2024","unstructured":"Gonzalez-Manzanares R, Anguita Gamez M, Muniz Garcia J, Barrios Alonso V, Perez Perez A, Gimeno Orna J et al (2024) Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study. Eur Heart J 45(Supplement_1):ehae666. 2613","journal-title":"Eur Heart J"},{"key":"5740_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"150","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8\u201316","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"5740_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A et al (2017) Effect of liraglutide, a glucagon-like peptide\u20101 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double\u2010blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5740_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12471-021-01579-2","volume":"30","author":"M Wijnen","year":"2022","unstructured":"Wijnen M, Duschek E, Boom H, van Vliet M (2022) The effects of antidiabetic agents on heart failure. Neth Heart J 30(2):65\u201375","journal-title":"Neth Heart J"},{"issue":"7","key":"5740_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70187","volume":"86","author":"MV Trivedi","year":"2025","unstructured":"Trivedi MV, Jadhav HR, Gaikwad AB (2025) Emerging in diabetic cardiomyopathy: molecular pathways and targets for therapeutic intervention. Drug Dev Res 86(7):e70187","journal-title":"Drug Dev Res"},{"issue":"2","key":"5740_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/cvr\/cvy226","volume":"115","author":"V Malek","year":"2019","unstructured":"Malek V, Gaikwad AB (2019) Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy. Cardiovasc Res 115(2):373\u2013384","journal-title":"Cardiovasc Res"},{"issue":"1","key":"5740_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.diabres.2008.07.003","volume":"82","author":"A Yamana","year":"2008","unstructured":"Yamana A, Arita M, Furuta M, Shimajiri Y, Sanke T (2008) The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract 82(1):127\u2013131","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"5740_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.diabres.2006.11.014","volume":"77","author":"I Usui","year":"2007","unstructured":"Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y et al (2007) Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77(2):210\u2013214","journal-title":"Diabetes Res Clin Pract"},{"issue":"17","key":"5740_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1136\/hrt.2011.225193","volume":"97","author":"SJ Hong","year":"2011","unstructured":"Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS, Lim D-S (2011) Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart 97(17):1425\u20131432","journal-title":"Heart"},{"issue":"6","key":"5740_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00424-012-1170-3","volume":"464","author":"HK Kim","year":"2012","unstructured":"Kim HK, Youm JB, Lee SR, Lim SE, Lee S-Y, Ko TH et al (2012) The angiotensin receptor blocker and PPAR-\u03b3 agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action. Pfl\u00fcgers Archiv-Eur J Physiol 464(6):631\u2013643","journal-title":"Pfl\u00fcgers Archiv-Eur J Physiol"},{"issue":"3","key":"5740_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00380-009-1186-6","volume":"25","author":"A Aoki","year":"2010","unstructured":"Aoki A, Ogawa T, Sumino H, Kumakura H, Takayama Y, Ichikawa S et al (2010) Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. Heart Vessels 25(3):195\u2013202","journal-title":"Heart Vessels"},{"issue":"46","key":"5740_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036098","volume":"102","author":"Y-G Yoo","year":"2023","unstructured":"Yoo Y-G, Lim M-J, Kim J-S, Jeong H-E, Ko H, Shin J-Y (2023) Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. Medicine (Baltimore) 102(46):e36098","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"5740_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/0115701611361265250211062540","volume":"23","author":"S Chauhan","year":"2025","unstructured":"Chauhan S, Bhandari U, Habib A (2025) Efficacy of dapagliflozin and telmisartan combination therapy in reducing albuminuria and inflammatory markers in diabetic nephropathy: a prospective observational study. Curr Vasc Pharmacol 23(6):441\u2013450","journal-title":"Curr Vasc Pharmacol"},{"key":"5740_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123570","volume":"370","author":"W Huang","year":"2025","unstructured":"Huang W, He C, Kim HI, Gao X, You J, Shao T et al (2025) MMP3 as a new target of Danshensu\/tetramethylpyrazine derivative for attenuating cardiac fibrosis post-myocardial infarction. Life Sci 370:123570","journal-title":"Life Sci"},{"key":"5740_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116541","volume":"229","author":"K Wang","year":"2024","unstructured":"Wang K, Zhou Y, Wen C, Du L, Li L, Cui Y et al (2024) Protective effects of tetramethylpyrazine on myocardial ischemia\/reperfusion injury involve NLRP3 inflammasome suppression by autophagy activation. Biochem Pharmacol 229:116541","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"5740_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/17085381211051477","volume":"30","author":"H Li","year":"2022","unstructured":"Li H, Yang M (2022) Ligustrazine activate the PPAR-\u03b3 pathway and play a protective role in vascular calcification. Vascular 30(6):1224\u20131231","journal-title":"Vascular"},{"key":"5740_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172763","volume":"865","author":"U Rai","year":"2019","unstructured":"Rai U, Kosuru R, Prakash S, Tiwari V, Singh S (2019) Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats. Eur J Pharmacol 865:172763","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5740_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12951-025-03667-6","volume":"23","author":"H Shi","year":"2025","unstructured":"Shi H, Pang B, Zhang F, Guo Z, Xu W, Zheng M et al (2025) A novel ligustrazine-based nanodelivery system protects against doxorubicin-induced cardiotoxicity by targeting the SIRT5\u2013DUSP1 axis for mitochondrial repair. J Nanobiotechnol 23(1):681","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"5740_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1745-7254.2005.00141.x","volume":"26","author":"Jn YANG","year":"2005","unstructured":"YANG Jn, CHEN Jm, Luo L, LIN Sc, Li D (2005) Tetramethylpyrazine protected photoreceptor cells of rats by modulating nuclear translocation of NF-\u03baB 1. Acta Pharmacol Sin 26(7):887\u2013892","journal-title":"Acta Pharmacol Sin"},{"key":"5740_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2014.12.008","volume":"748","author":"S Malik","year":"2015","unstructured":"Malik S, Suchal K, Gamad N, Dinda AK, Arya DS, Bhatia J (2015) Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol 748:54\u201360","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"5740_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/cbin.70078","volume":"49","author":"MV Trivedi","year":"2025","unstructured":"Trivedi MV, Jadhav HR, Gaikwad AB (2025) A novel combination of exogenous klotho combined with telmisartan ameliorated diabetic cardiomyopathy via an antifibrotic mechanism. Cell Biol Int 49(12):1669\u20131681","journal-title":"Cell Biol Int"},{"key":"5740_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120975","volume":"358","author":"YK Talati","year":"2025","unstructured":"Talati YK, Gaikwad AB (2025) Exploring the anti-fibrotic potential of gramine in a UUO-induced rat model of chronic kidney disease: a network pharmacology and molecular docking approach with experimental validation. J Ethnopharmacol 358:120975","journal-title":"J Ethnopharmacol"},{"key":"5740_CR24","doi-asserted-by":"publisher","first-page":"156402","DOI":"10.1016\/j.prp.2026.156402","volume":"281","author":"R Bhadange","year":"2026","unstructured":"Bhadange R, Gaikwad AB (2026) Modulation of AKT\/GSK-3\u03b2 signaling by ambrisentan alleviates chronic kidney disease. Pathol-Res Pract 281:156402","journal-title":"Pathol-Res Pract"},{"key":"5740_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116836","volume":"236","author":"U Rai","year":"2019","unstructured":"Rai U, Kosuru R, Prakash S, Singh SP, Birla H, Tiwari V et al (2019) Tetramethylpyrazine prevents diabetes by activating PI3K\/Akt\/GLUT-4 signalling in animal model of type-2 diabetes. Life Sci 236:116836","journal-title":"Life Sci"},{"key":"5740_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.112045","volume":"135","author":"Y Li","year":"2025","unstructured":"Li Y, Chen X, Yang M, Yan C, Zhang R, Zhang X et al (2025) Tetramethylpyrazine protects against myocardial ischemia\/reperfusion injury via regulating Myl2-mediated NLRP3 signaling pathway inhibition. Cell Signal 135:112045","journal-title":"Cell Signal"},{"issue":"9","key":"5740_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"Collaboration, E.R.F.","year":"2011","unstructured":"Collaboration, E.R.F. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829\u2013841","journal-title":"N Engl J Med"},{"issue":"1","key":"5740_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11154-010-9131-7","volume":"11","author":"S Boudina","year":"2010","unstructured":"Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metabolic Dis 11(1):31\u201339","journal-title":"Rev Endocr Metabolic Dis"},{"issue":"2\u20133","key":"5740_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ejphar.2011.04.008","volume":"660","author":"H Furukawa","year":"2011","unstructured":"Furukawa H, Mawatari K, Koyama K, Yasui S, Morizumi R, Shimohata T et al (2011) Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor \u03b3 in 3T3-L1 adipocytes. Eur J Pharmacol 660(2\u20133):485\u2013491","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"5740_CR30","doi-asserted-by":"publisher","first-page":"25723","DOI":"10.1007\/s11356-021-17831-6","volume":"29","author":"ME Youssef","year":"2022","unstructured":"Youssef ME, El-Azab MF, Abdel-Dayem MA, Yahya G, Alanazi IS, Saber S (2022) Electrocardiographic and histopathological characterizations of diabetic cardiomyopathy in rats. Environ Sci Pollut Res 29(17):25723\u201325732","journal-title":"Environ Sci Pollut Res"},{"key":"5740_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.980625","volume":"9","author":"T Burton","year":"2022","unstructured":"Burton T, Ramchandani S, Bhavnani SP, Khedraki R, Cohoon TJ, Stuckey TD et al (2022) Identifying novel phenotypes of elevated left ventricular end diastolic pressure using hierarchical clustering of features derived from electromechanical waveform data. Front Cardiovasc Med 9:980625","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"5740_CR32","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1177\/15353702211035058","volume":"246","author":"D Chang","year":"2021","unstructured":"Chang D, Xu T-T, Zhang S-J, Cai Y, Min S-D, Zhao Z et al (2021) Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. Exp Biol Med 246(23):2511\u20132521","journal-title":"Exp Biol Med"},{"issue":"1","key":"5740_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13020-020-00345-7","volume":"15","author":"Q Chen","year":"2020","unstructured":"Chen Q, Zhang D, Bi Y, Zhang W, Zhang Y, Meng Q et al (2020) The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism. Chin Med 15(1):63","journal-title":"Chin Med"},{"key":"5740_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2024.12.002","volume":"199","author":"L Wang","year":"2025","unstructured":"Wang L, Sang W, Jian Y, Han Y, Wang F, Wubulikasimu S et al (2025) MAPK14\/AIFM2 pathway regulates mitophagy-dependent apoptosis to improve atrial fibrillation. J Mol Cell Cardiol 199:1\u201311","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"5740_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12951-025-03420-z","volume":"23","author":"J Wang","year":"2025","unstructured":"Wang J, Zhuang H, Li C, Cai R, Shi H, Pang B et al (2025) Ligustrazine nano-drug delivery system ameliorates doxorubicin-mediated myocardial injury via piezo-type mechanosensitive ion channel component 1-prohibitin 2-mediated mitochondrial quality surveillance. J Nanobiotechnol 23(1):383","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"5740_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cbf.3383","volume":"37","author":"Y Wang","year":"2019","unstructured":"Wang Y, Xue J, Li Y, Zhou X, Qiao S, Han D (2019) Telmisartan protects against high glucose\/high lipid-induced apoptosis and insulin secretion by reducing the oxidative and ER stress. Cell Biochem Funct 37(3):161\u2013168","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"5740_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/ijms22010412","volume":"22","author":"CL Moore","year":"2021","unstructured":"Moore CL, Savenka AV, Basnakian AG (2021) TUNEL assay: a powerful tool for kidney injury evaluation. Int J Mol Sci 22(1):412","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5740_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00125-024-06325-y","volume":"68","author":"ST de Vries","year":"2025","unstructured":"de Vries ST, Pena MJ, Tye SC, Peters SA, van Raalte DH, Arnott C et al (2025) Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials. Diabetologia 68(3):507\u2013515","journal-title":"Diabetologia"},{"issue":"1","key":"5740_CR39","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/13880209.2020.1859554","volume":"58","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhang J, Wu D, Cui L (2020) Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. Pharm Biol 58(1):1299\u20131302","journal-title":"Pharm Biol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05740-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:41Z","timestamp":1792569341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05740-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5740"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05740-6","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this research, the animal protocol was approved by the Institutional Animal Ethics Committee (IAEC) of Birla Institute of Technology and Science Pilani (BITS-Pilani) (Protocol Approval No: IAEC\/RES\/37\/09). Throughout the animal experimentation, the ARRIVE guidelines were followed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}